Navigation Links
ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
Date:8/4/2009

EXTON, Pa., Aug. 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Pharmaceutical Science and Clinical Pharmacology Advisory Committee supports the FDA's Office of Generic Drugs (OGD) draft guidelines on bioequivalence (BE) for Vancocin(R) (vancomycin hydrochloride) capsules. Vancocin is used to treat severe, often life-threatening bacterial infections of the gastrointestinal (GI) tract, Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus. The draft guidelines, if approved, would allow generic manufacturers to use less rigorous standards, including in vitro rather than in vivo testing, for establishing BE rather than using comparative clinical trials. ViroPharma scientists and other leading experts voiced their concern that these new guidelines could jeopardize patient safety.

"We're appreciative that the FDA convened this advisory committee to provide a forum for open debate and discussion regarding a serious public health issue," said Vincent J. Milano, ViroPharma's president and chief executive officer. "While we're disappointed with the vote, we hope that the OGD will take every precaution to ensure that CDI patients will be treated with truly bioequivalent versions of vancomycin, given the life-threatening nature of the disease."

The Advisory Committee was asked if the proposed OGD guidelines and the use of in vitro dissolution methods are sufficient for establishing bioequivalence for generic vancomycin oral capsules. The Advisory Committee voted unanimously in favor of the proposed OGD recommendation to demonstrate bioequivalence through equivalent dissolution in media of pH 1.2, 4.5 and 6.8 for potential vancomycin HCl capsule
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
2. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
3. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
4. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
5. ViroPharma to Present at Two May Healthcare Conferences
6. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
7. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
8. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
9. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
10. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. ViroPharma Provides Update on Vancocin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... (PRWEB) November 28, 2014 On Monday, ... and Sendik’s will present Feeding America Eastern Wisconsin with ... Food Market to donate a portion of proceeds to ... Sendik’s promotion, “7 Days, 7 Ways to Save” with ... Fyffes pineapples were two for $4 and Turbana bananas ...
(Date:11/28/2014)... Walder, one of South Florida’s top cosmetic dermatologists , ... that is designed to help her patients reduce unwanted fat ... has been praised by patients as being permanent, painless, and ... types of external fat reduction. , “If you can pinch ... According to Dr. Walder, Ultrashape works by targeting subcutaneous fat, ...
(Date:11/28/2014)... 2014 The Alternative Health ... the past five years. The industry has been ... that are either alternative to conventional Western medicine ... industry analyst David Whytcross, “industry revenue has been ... private health insurance membership.” Meanwhile, improving economic conditions ...
(Date:11/28/2014)... (HealthDay News) -- Celebration can quickly turn to ... Day, experts say. Over the last decade, more ... while people were using turkey fryers, according to the ... cared for a patient who tried to deep fry ... in any circumstances," Dr. Arthur Sanford, a burn surgeon ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin ... parabens and other cancer-causing agents, but they are also ... awareness programs that help in the fight against breast ... an incredible, record-breaking contribution of $30,000 through participation in ... Sweet Red Rose Whip Moisturizer and the company’s corporate ...
Breaking Medicine News(10 mins):Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 3Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3
... ... company manages to grow sales and reduce its impact on the environment. ... row, Service Foods, the largest Home Food service company in America, discovered ... Carbon Neutral once again measured and offset 100% of Service Foods’ scope ...
... , ... branded electronic data room infrastructure announced a 237% year over year revenue growth. Unlimited use ... ... data room infrastructure for corporate transactions and secure extranets today announced that it had ...
... LYON, France , February ... of TCS 7560 and TCS 7561 Silbione(R) products designed,for the ... medical equipment). These two new silicone elastomers have,excellent "anti-slip" non-compression ... http://www.newscom.com/cgi-bin/prnh/20100216/377913 ) , Self-fixing ...
... ... is in compliance with SAS 70 recommended best practices related to internal controls. ... Bellevue, WA (PRWEB) ... solutions, announced today that the company has received its completed SAS 70 Type II ...
... While jury deliberates after ... as result of 2005 accident , ... York, NY (Lexis Nexis) February 16, 2010 -- Seth Harris , partner in the ... resident who was badly injured while walking to work on an icy winter day in 2005., ...
... of autism in infants, comparing the behavior of the siblings ... normally, has found that the nascent symptoms of the condition ... babbling are not present at 6 months, but emerge ... the first year of life. Researchers conducted the study ...
Cached Medicine News:Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 2Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 3Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 2Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 3Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 4Health News:Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications 2Health News:Corporate Wellness Firm Limeade Receives SAS 70 Type II Report 2Health News:New York Law Firm Secures $750,000 Settlement for Bronx Man Injured in Slip and Fall Accident 2Health News:Autism's earliest symptoms not evident in children under 6 months 2Health News:Autism's earliest symptoms not evident in children under 6 months 3Health News:Autism's earliest symptoms not evident in children under 6 months 4
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... President and Chief Executive Officer, will present at the Bank of ... , , , Date: , , , Wednesday, December 3, ... p.m. EST , , , , Location: , , , ... About BioScrip, Inc. BioScrip, Inc. is ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader ... cell immunotherapy to treat a variety of cancers, today ... by BVCF, a China -based healthcare ... immunotherapy company focused on the development of new therapeutics ... with Shanghai Cancer Institute and Shanghai Renji Hospital, the ...
(Date:11/26/2014)... and NEW YORK ... As the leading distributor of market intelligence, ... new research report by IQ4I Research and Consultancy focusing ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast to ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
... 19, 2011 Johnson & Johnson (NYSE: JNJ ... the investment community beginning at 9:00 a.m. (Eastern Time) on ... Brunswick, N.J. ending at approximately 3:00 p.m. Sheri ... Duato and Paul Stoffels, M.D. will host the meeting and ...
... data from multiple clinical trials supporting the safety and ... dual antiplatelet therapy (DAPT) is not advisable were featured ... and treat patients who are not suitable candidates for ... Presenters discussed current treatment alternatives to drug ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 2OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 3OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 4
... The LH 755 simplifies ... by integrating expert automation and ... It delivers reliable, accurate results ... the best slide quality with ...
For the quantitative determination of Creatine Kinase in serum....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
For the quantitative determination of total glucose in serum....
Medicine Products: